- 询价
- Leading Biology
- LBP60459
- 美国
- 2025年07月10日
企业认证
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 保存条件：
Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.
- 英文名：
Anti-Human Osteopontin (C-Terminal) Antibody
- 供应商：
安诺伦（北京）生物科技有限公司
靶点/蛋白：ABD10896 recognises an epitope within the C-terminal (CT) region of osteopontin, an acid-rich, multidomain, phosphorylated 60kD glycoprotein. Osteopontin is a secreted chemokine-like protein that is a member of the SIBLING family, and is synthesised by many cell types. Osteopontin is involved in enhancing production of interferon-gamma and interleukin-12 and reducing production of interleukin-10. It is essential in the pathway that leads to type I immunity. Osteoponitn is also thought to be important to cell-matrix interaction, and can bind fibronectin, collagen and calcium. Osteopontin has been suggested to have a role in atherosclerosis, bone remodelling, angiogenesis, wound healing and tissue injuries.
来源：Goat
参考文献：1. Rangaswami, H. et al. (2006) Osteopontin: role in cell signaling and cancer progression.
Trens Cell Biol. 16: 79-87.
特异性：Human
别名：Osteopontin, Bone sialoprotein 1, Nephropontin, Secreted phosphoprotein 1, SPP-1, Urinary stone protein, Uropontin, SPP1, BNSP, OPN
简单描述：Goat Polyclonal Anti-Human Osteopontin (C-Terminal) Antibody . Validated for use in WB, E.
生物商城：http://www.annoron.com
办公电话：010-56256916
官方售后：400-965-8633
企业 QQ：3212874516、3198592576
地 址：北京大兴经济技术开发区(亦庄)同济中路7号兴盛国际A栋4层
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验.: AR3A, human anti‐HCV E2 antibody (Law et al., ) E910, mouse anti‐HCV NS5A antibody (Lindenbach et al
antibody at 5 µg/ml for 45 min at 4 °C. Mouse anti-human NFB p65 monoclonal antibody sc-8008 (Santa Cruz, CA, USA) recognizes epitopes mapping the C amino-acid terminus of human origin NFB p65. After two washes in PBS–FCS, nuclei were incubated for 45 min
PriCells: Primary cells culture with supplement of vascular endothelial growth factor (VEGF)
, move, or further differentiate. Hence, VEGF is a potential target for the treatment of cancer. The first anti-VEGF drug, a monoclonal antibody named bevacizumab, was approved in 2004. Approximately 10-15% of patients benefit from bevacizumab therapy; however, biomarkers
技术资料暂无技术资料 索取技术资料
